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ABSTRACT
Aim: Cerebral hypoxia has been associated with neurodevelopmental impairment. We
studied whether reducing cerebral hypoxia in extremely preterm infants during the first
72 hours of life affected neurological outcomes at two years of corrected age.
Methods: In 2012-2013, the phase II randomised Safeguarding the Brains of our smallest
Children trial compared visible cerebral near-infrared spectroscopy (NIRS) monitoring in an
intervention group and blinded NIRS monitoring in a control group. Cerebral hypoxia was
significantly reduced in the intervention group. We followed up 115 survivors from eight
European centres at two years of corrected age, by conducting a medical examination and
assessing their neurodevelopment with the Bayley Scales of Infant and Toddler
Development, Second or Third Edition, and the parental Ages and Stages Questionnaire
(ASQ).
Results: There were no differences between the intervention (n = 65) and control
(n = 50) groups with regard to the mean mental developmental index (89.6  19.5
versus 88.4  14.7, p = 0.77), ASQ score (215  58 versus 213  58, p = 0.88) and
the number of children with moderate-to-severe neurodevelopmental impairment (10
versus six, p = 0.58).
Conclusion: Cerebral NIRS monitoring was not associated with long-term benefits or harm
with regard to neurodevelopmental outcome at two years of corrected age.
INTRODUCTION
Being born extremely preterm carries a 20% risk of death,
and 25% of survivors have moderate-to-severe neurodevel-
opmental impairment, namely cerebral palsy (CP) or cog-
nitive impairment (1). The respiratory and circulatory
systems of extremely preterm infants are immature, and
cerebral autoregulation is impaired, especially during the
transition from intrauterine to extrauterine life (2–4). In
addition, oxygen transport may be impaired by low
haemoglobin levels (5) and this makes the developing
premature brain susceptible to fluctuations in cerebral
blood flow (6). In addition, haemodynamic instability may
cause episodes of cerebral hypoxia and hyperoxia, which
have been associated with intracranial haemorrhage,
ischaemic lesions and later neurodevelopmental impair-
ment (7). The phase II randomised Safeguarding the Brains
of our smallest Children (SafeBoosC II) clinical trial
demonstrated the possibility of reducing the burden of
Abbreviations
ASQ, Ages and stages questionnaire; CP, Cerebral palsy; GMFCS,
Gross motor function classification system; MDI, Mental devel-
opmental index; NIRS, Near-infrared spectroscopy.
Key notes
 We studied whether reducing cerebral hypoxia in
extremely preterm infants during the first 72 hours of
life affected neurological outcomes at two years of
corrected age.
 The Safeguarding the Brains of our Smallest Children
trial followed up 115 survivors from eight European
centres by assessing their neurodevelopment.
 Cerebral NIRS monitoring was not associated with long-
term benefits or harm with regard to neurodevelop-
ment at two years of corrected age.
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cerebral hypoxia and hyperoxia during the first 72 hours of
life (8) and found that only hypoxia was reduced. The aim
of this follow-up study was to assess the neurodevelopmen-
tal outcomes of infants included in the SafeBoosC II trial
when they reached two years of corrected age.
METHODS
Patients
Between June 2012 and December 2013, 166 extremely
preterm infants from eight European countries – Austria,
Denmark, France, Ireland, Italy, Spain, the Netherlands
and the United Kingdom – were included in the SafeBoosC
II trial (8). The infants were randomised to either experi-
mental or control groups before they were three hours of
age, and both groups were monitored with continuous
cerebral tissue oxygenation by near-infrared spectroscopy
(NIRS). In the intervention group, the cerebral oxygenation
level was visible and the target range was set at 55% to 85%.
The clinicians were provided with a dedicated treatment
guideline listing possible interventions if the cerebral oxy-
genation was out of range (9). In the control group, the
cerebral oxygenation levels were recorded, but the clini-
cians were blinded to the results and the infants were given
standard treatment and care. Cerebral monitoring was
conducted from three hours until 72 hours after birth. The
burden of cerebral hypoxia and hyperoxia was reduced by
58% in the intervention group, with a 95% confidence
interval (95% CI) of 35%–73% (p < 0.001) (8). The burden
of cerebral hypoxia and hyperoxia was calculated as the
time spent below or above the target limits, multiplied by
the mean deviation from the lower (55%) or the upper limit
(85%) during the first 72 hours of life, expressed in the
percentage of hours. The burden was computed from un-
edited NIRS values and extrapolated to 72 hours, without
the knowledge of any other outcomes of the trial. The
protocol of the SafeBoosC II trial has been published (10)
and is available in full at www.safeboosc.eu. The trial was
registered at ClinicalTrial.gov (NCT01590316).
Follow-up at two years of corrected age
At a corrected age of two years, the children were invited to
participate in the SafeBoosC II follow-up study. Their
neurodevelopment was assessed with the Bayley Scales of
Infant and Toddler Development, Second Edition (Bayley-
II) or Third Edition (Bayley-III), depending on what version
the centre was using at the time of the study. In addition,
their parents were asked to complete the Ages and Stages
Questionnaire (ASQ) and the children also underwent a
medical examination.
The Bayley-II and Bayley-III tests
At the corrected age of 23–25 months, the children under-
went the Bayley-II or Bayley-III test. If the children were ill,
tired or unable to be assessed on the day of the test for any
other reason, the parents were offered a new consultation.
We combined the results of the Bayley-II and Bayley-III
tests by converting the Bayley-III language and cognitive
scores into a predicted mental developmental index (MDI)
score according to a previously published algorithm (11).
The psychologists conducting the tests were blinded to
which group the infant was in.
The ASQ
The ASQ is a set of parental questionnaires covering the
development of children aged from four months to five
years. Each questionnaire contains five developmental
domains, which each provides six questions covering
communications, gross motor skills, fine motor skills,
problem solving and personal–social skills. Previously, the
agreement between ASQ and concurrent assessment by
Bayley third edition has been good and ASQ may be a
substitute for Bayley test in cases or at centres where the
Bayley test is not possible (12). The ASQ was originally
developed as a screening tool, and infants with normal
development achieve near maximum scores, resulting in
an overestimation of the mean. Therefore, the ASQ for
slightly older children, aged 25 months and 16 days to
28 months and 15 days, was chosen to achieve normal
distribution of the data (13). At the corrected age of 23–
25 months, the ASQ was sent to the parents together
with a prestamped envelope so that they could return
questionnaire. The parents were not blinded to the
intervention.
The medical examination
Basic growth measurements were collected, namely head
circumference, height and weight, and vision and auditory
functions were evaluated. If the children showed signs of
cerebral palsy, the gross motor function was assessed using
the Gross Motor Function Classification System (GMFCS).
The doctor performing the medical examination was not
blinded to the intervention.
Neurodevelopmental impairment was classified accord-
ing to classification of health status at two years as a
perinatal outcome, which was developed by the British
Association of Perinatal Medicine (14). The child was
diagnosed with severe neurodevelopmental disability if any
of the following conditions were present: CP with a GMFCS
score of 3–5; a cognitive function score below -3 standard
deviations scores (MDI below 55); hearing impairment with
no useful hearing even with aids; no meaningful words or
signs; and blind or only able to perceive light or light-
reflecting objects. The child was diagnosed with moderate
neurodevelopmental disability if any of the following
conditions were present: CP with a GMFCS score of 1–2;
a cognitive function score between -3 and -2 standard
deviations scores (MDI 55–70); hearing impairment, but
useful hearing with aids; fewer than five words or signs; and
moderately impaired vision.
Statistical methods
The baseline characteristics and the two-year outcomes
were compared between the two intervention groups using
unpaired t-tests or the chi-square test where appropriate.
All p values are two-tailed.
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Ethics
The SafeBoosC II trial was approved by each hospital’s
research ethics committee: the Hopital Femme Mere
Enfants, Lyon, France; the Rigshospitalet, Copenhagen,
Denmark; the La Paz University Hospital, Madrid, Spain;
the Cork University Maternity Hospital, Cork, Ireland; the
Wilhelmina Children’s Hospital, Utrecht, the Netherlands;
the Medical University of Graz, Graz, Austria; the Fon-
dazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milan, Italy, and the Rosie Hospital, Cambridge University
Hospitals, the United Kingdom. Austria, Denmark, and
France also required the approval of the authority respon-
sible for medical devices. Written, informed parental con-
sent was obtained before inclusion in the trial, and the
parents gave their consent for the data collection and
follow-up before randomisation.
RESULTS
Of the 166 extremely preterm infants included in the
SafeBoosC II trial, 32 died before their expected date of
delivery and three more died shortly afterwards. Of the
remaining 131 children, the two-year follow-up was con-
ducted in 115 children (Fig. 1). The 65 infants in the
intervention group were predominantly male (54%), 24%
were twins, and they had an average gestational age of
26.6  1.1 weeks and average birthweight of 863  208
grams. The 50 infants in the control group were predom-
inantly female (62%), 22% were twins, and they had an
average gestational age of 26.7  1.2 weeks and an average
birthweight of 901  204 g (Table 1).
Because we were unable to obtain any information
about 16 of the 131 children, their status was recorded as
unknown (Table 2). However, we do know that they had
significantly fewer antenatal steroids and were more likely
to have been born after prolonged rupture of the mem-
branes than the 115 children who were followed up. There
was also a tendency towards a lower mean gestational age
(26.1  1.1 weeks) in the children with unknown status at
two years of age (Table 2). The flow of patients from
inclusion to the two-year follow-up is presented in
Figure 1.
As expected in the infants followed up at two years of
corrected age, there was a significantly lower burden of total
cerebral hypoxia and hyperoxia in the intervention group
(32% of hours) versus the control group (68% of hours,
p < 0.01), whereas there were no differences in other
patient characteristics (Table 1). The Bayley-II and
Bayley-III and the ASQ findings did not differ between
the groups (Table 3), and the number of infants with
moderate-to-severe developmental delay was similar, at 10
(15%) in the intervention group and six (12%) in the control
group (p = 0.58). The combined mean MDI did not differ
between the groups, with a score of 89.l6  19.5 for the
intervention group and 88.4  14.7 for the control group
(p = 0.77).
The categorisations for the 16/115 (14%) of the children
with moderate-to-severe developmental delay are presented
in Table 4. The combined outcome of death or moderate-
to-severe outcome at two years was not significant at 23
(26%) in the intervention group and 28 (35%) in the control
group (p = 0.20).
DISCUSSION
At two years of corrected age, 88% of the surviving
infants from the SafeBoosC II trial were followed up. We
found no difference between the MDI and ASQ results or
Figure 1 Trial participant flow in the SafeBoosC II clinical trial from randomisation within three hours of birth to follow-up at two years of corrected age.
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the number of children with moderate-to severe develop-
mental delays between the intervention and the control
groups. Moreover, there was no difference between the
groups when the composite adverse outcomes of death or
moderate-to-severe neurodevelopmental outcome were
assessed.
SafeBoosC II was a randomised clinical trial that inves-
tigated the possibility of reducing the burden of cerebral
hypoxia and hyperoxia during the first 72 hours of life in
extremely preterm infants, and the burden of cerebral
hypoxia was the primary outcome. This outcome enabled
us to calculate the sample size needed for a trial of this
Table 1 Baseline characteristics, burden of cerebral hypoxia and hyperoxia and neonatal complications in the intervention and control group
Intervention (n = 65) Control (n = 50) p value
Baseline characteristics
Gestational age (w) 26.6  1.1 26.7  1.2
Birthweight (g) 868  208 901  204
Male sex 54 38
Twins 24 22
Prenatal steroids 72 81
Prolonged rupture of membranes 26 40
Maternal clinical chorioamnionitis 6 6
Apgar score <5 at five minutes 18 16
Burden of cerebral hypoxia and hyperoxia
Burden of cerebral hypoxia (%h)* 16 (4–63) 50 (16–122) <0.01
Burden of cerebral hyperoxia (%h)* 1 (0.2–10) 0.7 (0.1–14) 0.83
Total burden of cerebral hypoxia and hyperoxia (%h)* 32 (9–78) 68 (38–143) <0.01
Neonatal complications
Severe brain injury on cUS** 11 16 0.58
Necrotising enterocolitis 11 10 >0.99
Bronchopulmonary dysplasia 57 48 0.35
Retinopathy of prematurity 18 10 0.29
Values are percentages unless stated otherwise.
*Median and (IQR) p values after log transformation.
**Severe injury was defined as intraventricular haemorrhage grade III, posthaemorrhagic ventricular dilatation, parenchymal/periventricular haemorrhagic
infarction, unilateral porencephalic cysts, cystic periventricular leucomalacia (bilateral), cerebellar haemorrhage, cerebral atrophy at term age or stroke (18).
Table 2 Baseline characteristics, burden of cerebral hypoxia and hyperoxia and neonatal complications in the infants with and without follow-up at two years
Follow-up (n = 115) No follow-up (n = 16) p value
Baseline characteristics
Gestational age (w) 26.7 (1.1) 26.1 (1.1) 0.06
Birthweight (g) 882 (206) 851 (172) 0.56
Male sex 53 63 0.29
Twins 23 6 0.19
Prenatal steroids 76 44 <0.05
Prolonged rupture of membranes 32 69 <0.05
Maternal clinical chorioamnionitis 6 13 0.28
Apgar score <5 at Five minutes 17 7 0.46
Burden of cerebral hypoxia and hyperoxia
Burden of cerebral hypoxia (% of hours)* 27 (8–78) 10 (4–86) 0.29
Burden of cerebral hyperoxia (% of hours)* 1 (0.1–13) 12 (3–32) <0.05
Total burden of cerebral hypoxia and hyperoxia (% of hours)* 50 (15–102) 42 (20–101) 0.88
Neonatal complications
Severe brain injury on cranial ultrasound** 14 7 0.69
Necrotising enterocolitis 10 13 0.68
Bronchopulmonary dysplasia 53 36 0.26
Retinopathy of prematurity 15 13 >0.99
Values are percentages unless stated otherwise.
*Median and (IQR) p values after log transformation.
**Severe injury was defined as intraventricular haemorrhage grade III, posthaemorrhagic ventricular dilatation, parenchymal/periventricular haemorrhagic
infarction, unilateral porencephalic cysts, cystic periventricular leucomalacia (bilateral), cerebellar haemorrhage, cerebral atrophy at term age or stroke (18).
278 ©2018 The Authors. Acta Pædiatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Pædiatrica 2019 108, pp. 275–281
Neurodevelopmental outcomes after early cerebral oximetry Plomgaard et al.
nature (10), and we concluded that a trial powered to show
a potential difference between neurodevelopmental out-
comes would require approximately 10 times the number of
infants in the SafeBoosC II trial. Therefore, it is not
surprising that we found no difference in the neurodevel-
opmental outcomes between the intervention and control
groups.
In the SafeBoosC II trial, the eight participating centres
were allowed to conduct the two-year assessment using
either Bayley-II or Bayley-III. This approach was taken as
the centres used different editions for the routine follow-up
of preterm infants and we did not think it was reasonable
for the children to undergo two similar tests. Bayley-III is
known to yield higher scores than Bayley-II, particularly in
infants who perform in the low range (15), but this was not
expected to bias the comparisons between the groups.
Therefore, we converted the cognitive and language indexes
from Bayley-III into a predicted MDI score (11). We found
no significant differences between the intervention groups
in either of the Bayley tests or in the combined MDI score.
Almost a quarter of the infants in the follow-up were twins,
but only six pairs of twins participated in one of the Bayley
tests and only seven pairs of twins took part in the ASQ test.
As the statistical effects were small and all the neurodevel-
opmental effects were insignificant, we choose not to
correct the data for any twin correlation.
Observational studies have found that cerebral hypoxia
during the transition from intrauterine to extrauterine life
has been associated with an increased risk of intracranial
haemorrhage, ischaemic lesions and later developmental
impairment (7,16). The benefits of cerebral NIRS monitor-
ing need to be proven in randomised clinical trials, before
the method is routinely applied to extremely premature
infants (17). The SafeBoosC II trial was the first randomised
clinical trial to investigate the possibility of reducing the
burden of cerebral hypoxia and hyperoxia in extremely
preterm infants. During the trial, fewer infants died and
fewer infants had severe brain injuries on cranial ultrasound
in the intervention group than in the control group, but
these results were not statistically significant (8,18). More-
over, the biomarkers of brain injury used in the SafeBoosC
II trial did not differ between the intervention groups. These
were amplitude-integrated electroencephalography at
64 hours of age and S100 beta, neuroketal and brain fatty
acid-binding protein at six and 64 hours of age (19).
However, post hoc analysis showed clear associations
between the burden of cerebral hypoxia, severe brain
injuries on cranial ultrasound, reduced electrical activity
on amplitude-integrated electroencephalography and
death (20).
When the extremely preterm infants reached term age,
the mortality in the SafeBoosC II trial was 19%. We found
that five children in the trial had severe developmental
delay, according to the British Association of Perinatal
Medicine definition (14), and further 11 children were
diagnosed with moderate developmental delay. These
numbers correspond to 6% (5/83) with severe develop-
mental delay and 19% (16/83) with moderate-to-severe
developmental delay. These numbers were slightly lower
than expected for extremely preterm infants. We were
unable to obtain follow-up data on 16 of the 131 children.
In observational studies, infants lost to follow-up often have
lower socioeconomic status and tend to have more devel-
opmental delays than infants attending follow-up pro-
grammes (21). If all of these 16 infants lost to follow-up
were diagnosed with moderate-to-severe developmental
delay, the percentage affected would have been 28%. In
our trial, the number of infants lost to follow-up was similar
Table 3 Follow-up at two years of corrected age using Bayley-II, Bayley-III and ASQ
Intervention Control p value
Bayley-II (n) 14 16
Age at Bayley-II (months) 25.0 (1.4) 24.8 (1.1) 0.65
Mental Developmental Index 96.9 (13.9) 86.4 (13.8) 0.05
Psychomotor
Developmental Index
83.9 (14.3) 87.4 (16.0) 0.54
Bayley-III (n) 30 23
Age at Bayley-III (months) 24.3 (3.6) 25.2 (2.9) 0.34
Cognitive index 95.8 (19.9) 97.6 (10.2) 0.69
Language index 94.4 (18.8) 95.6 (13.4) 0.81
Motor index 91.8 (15.6) 99.1 (9.2) 0.07
Predicted Mental
Developmental Index*
85.6 (21.1) 90.0 (15.4) 0.43
Ages and Stages
Questionnaire (n)
48 42
Age at ASQ (months) 25.7 (3.3) 25.6 (3.4) 0.88
Gross motor score 39.7 (15.9) 44.5 (14.6) 0.14
Fine motor score 42.7 (14.9) 44.3 (10.9) 0.57
Communication score 46.1 (14.4) 40.6 (15.7) 0.08
Personal social score 43.4 (14.1) 41.4 (13.2) 0.48
Problem solving score 43.3 (12.3) 42.6 (13.8) 0.80
Total ASQ score 215.3 (58.0) 213.4 (58.4) 0.88
Medical examination (n) 45 37
Age (months) 24.6 (3.1) 24.8 (2.3) 0.69
Head circumference
(centimetres)
48.0 (1.8) 48.1 (1.6) 0.75
Weight (kilograms) 11.2 (1.7) 11.0 (1.4) 0.85
Height (centimetres) 85.4 (4.6) 85.0 (4.8) 0.67
Cerebral palsy (number) 3 2 >0.99
GMFCS for patients with CP** 1, 2, 2 1, 4 –
Hearing impairment (number) 0 0 –
Moderate vision
impairment†(number)
2 2 >0.99
Severe vision
impairment††(number)
0 0 –
Combined outcome (n) 45 38
Moderate neurodevelopmental
impairment§(number)
8 3 0.21
Severe neurodevelopmental
impairment§§ (number)
2 3 >0.99
*predicted MDI of the Bayley-II as calculated from the cognitive and language
indices.
**GMFCS, Gross Motor Function Classification System.
†vision impaired but better than severe vision impairment.
††blind or only able to perceive light or light-reflecting objects.
§ and §§ see classification of neurodevelopmental impairment in Patients and
Methods section.
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in the intervention and control groups. The burden of
cerebral hyperoxia was higher for the infants lost to follow-
up than the children attending the follow-up programme,
and we suggest this was caused by multiple comparisons, as
the burden of hyperoxia was negligible in the SafeBoosC II
trial (8).
CONCLUSIONS
In conclusion, cerebral oxygenation monitoring was not
associated with adverse long-term outcomes in extremely
preterm infants. Successfully reducing cerebral hypoxia in
the SafeBoosC II trial intervention group was not reflected
in the MDI or the ASQ at two years of corrected age, and
the numbers of infants with moderate-to-severe neurode-
velopmental impairment were similar in the two interven-
tion groups. The SafeBoosC II trial was a feasibility trial
that was powered to prove only the possibility of reducing
the burden of cerebral hypoxia and hyperoxia. Larger
randomised clinical trials are needed to document clinically
relevant benefits, such as reductions in mortality, severe
brain injuries and/or neurodevelopmental deficits at follow-
up, before monitoring of cerebral oxygenation is routinely
introduced to the care of extremely preterm infants.
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